Isolation of phytoplasma DNA from the coconut palms (Cocos nucifera L.) collected from Ghana

This study aimed to verify the presence of the causative agent of Lethal Yellowing which is phytoplasma in samples provided from infected coconut trees. Study was carried out by using various samples like zygotic embryo, young leaves and immature & mature inflorescences. These materials were collected from trees at the stage 1 and 2 of the disease development.. Stage 1 of disease development is characterized by leaf yellowing and the start of the falling nuts while at the stage 2 of disease development, the trees has not bear nuts longer. From infected material, DNA was extracted by three different processes and isolated DNA was amplified by PCR. 16S rRNA gene was amplified by two specific primers of phytoplama viz P1/P2 and Ghana 813/AKSR. Among the various tested materials presence of phytoplasma was reported from the mature inflorescences while the presence of the phytoplasma was not reported from the leaves and embryos of the coconut

Isolation of phytoplasma DNA from the coconut palms (Cocos nucifera L.) collected from Ghana

This study aimed to verify the presence of the causative agent of Lethal Yellowing which is phytoplasma in samples provided from infected coconut trees. Study was carried out by using various samples like zygotic embryo, young leaves and immature & mature inflorescences. These materials were collected from trees at the stage 1 and 2 of the disease development.. Stage 1 of disease development is characterized by leaf yellowing and the start of the falling nuts while at the stage 2 of disease development, the trees has not bear nuts longer. From infected material, DNA was extracted by three different processes and isolated DNA was amplified by PCR. 16S rRNA gene was amplified by two specific primers of phytoplama viz P1/P2 and Ghana 813/AKSR. Among the various tested materials presence of phytoplasma was reported from the mature inflorescences while the presence of the phytoplasma was not reported from the leaves and embryos of the coconut

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial

International audienceIMPORTANCE: Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could have a detrimental effect on outcomes for these patients. OBJECTIVE: To compare the feasibility, efficacy, and safety of single-agent carboplatin every 3 weeks, weekly carboplatin-paclitaxel, or conventional every-3-weeks carboplatin-paclitaxel in vulnerable older patients with ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: This international, open-label, 3-arm randomized clinical trial screened 447 women 70 years and older with newly diagnosed stage III/IV ovarian cancer by determining their Geriatric Vulnerability Score; 120 patients with a Geriatric Vulnerability Score of 3 or higher were stratified by country and surgical outcome. Enrollment took place at 48 academic centers in France, Italy, Finland, Denmark, Sweden, and Canada from December 11, 2013, to April 26, 2017. Final analysis database lock April 2019. Data analysis was performed from February 1 to December 31, 2019. INTERVENTIONS: Patients were randomized to receive 6 cycles of (1) carboplatin, area under the curve (AUC) 5 mg/mL·min, plus paclitaxel, 175 mg/m2, every 3 weeks; (2) single-agent carboplatin, AUC 5 mg/mL·min or AUC 6 mg/mL·min, every 3 weeks; or (3) weekly carboplatin, AUC 2 mg/mL·min, plus paclitaxel, 60 mg/m2, on days 1, 8, and 15 every 4 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was treatment feasibility, defined as the ability to complete 6 chemotherapy cycles without disease progression, premature toxic effects-related treatment discontinuation, or death. RESULTS: A total of 120 women were randomized. The mean and median age was 80 (interquartile range, 76-83; range, 70-94) years; 43 (36%) had a Geriatric Vulnerability Score of 4 and 13 (11%) had a Geriatric Vulnerability Score of 5; 40 (33%) had stage IV disease. During its third meeting, the independent data monitoring committee's recommendation led to the termination of the trial because single-agent carboplatin was associated with significantly worse survival. Six cycles were completed in 26 of 40 (65%), 19 of 40 (48%), and 24 of 40 (60%) patients in the every-3-weeks combination, single-agent carboplatin, and weekly combination groups, respectively. Treatment-related adverse events were less common with the standard every-3-weeks combination (17 of 40 [43%]) than single-agent carboplatin or weekly combination therapy (both 23 of 40 [58%]). Treatment-related deaths occurred in 4 patients (2 of 40 [5%] in each combination group). CONCLUSIONS AND RELEVANCE: This randomized clinical trial shows that compared with every-3-weeks or weekly carboplatin-paclitaxel regimens, single-agent carboplatin was less active with significantly worse survival outcomes in vulnerable older patients with ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02001272

Global warming and planetary health: An open letter to the WHO from scientific and indigenous people urging for paleo-microbiology studies

International audienceThis article, written by a collective of international researchers and worldwide representatives of indigenous populations, is an open letter to the WHO, based on the latest elements from the scientific literature, and the latest climatological data. It takes stock of the health consequences of global warming, and urges research organizations to take an interest in infectious agents formerly stored in the layers of ground (frozen or not) and now mobilized, then released from a distance